PHILADELPHIA and VANCOUVER, British Columbia — November 4, 2025 — Leads & Copy — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) will present a poster at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting on November 7, 2025, showcasing the anti-cancer activity of its next-generation Bria-OTS+ platform in preclinical models.
The company’s lead candidates, Bria-BRES+™ (breast cancer) and Bria-PROS+™ (prostate cancer), have completed GMP manufacturing for planned clinical trials. Additionally, a $2 million National Cancer Institute (NCI) Small Business Innovative Research (SBIR) award supports the manufacturing and planned clinical evaluation of Bria-PROS+.
Bria-OTS+ is designed to express multiple immune-activating cytokines and co-stimulatory molecules to further enhance immune engagement, offering a novel and cost-effective approach to cancer therapy. The details of the poster presentation are as follows: Title: Redefining Cancer Vaccines: Bria-OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance; Abstract Number: 353; Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center; Date: Friday, November 7, 2025; Time: 12:15-1:45 PM, and 5:35-7 PM ET.
According to Dr. Miguel A. Lopez-Lago, BriaCell’s Chief Scientific Officer, the Bria-OTS+ platform is designed to reinvigorate the body’s immune system, allowing it to powerfully and selectively attack cancer cells while sparing normal tissues. Dr. William V. Williams, BriaCell’s President and CEO, the data further validates the promise of their personalized cancer immunotherapy platform in advancing new treatments for cancer.
Dr. William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Source: BriaCell Therapeutics Corp.
